AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26808615 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM(emph) in GOLD 1-4 participants
Number of subjects: 1508
Study 26808615 — intervention group
Group type: EXPERIMENTAL
Intervention: CT metrics contribution to FEV1 decline in GOLD 1/2
Number of subjects: 1508
Study 26808615 — intervention group
Group type: EXPERIMENTAL
Intervention: CT metrics contribution to FEV1 decline in GOLD 3/4
Number of subjects: 1508
Study 26808671 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg orally
Number of subjects: 24
Study 26809001 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour and Contour TS blood glucose monitoring systems
Number of subjects: 100
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drug use (e.g., marijuana, cocaine, heroin)
Number of subjects: 589
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug misuse
Number of subjects: 589
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking in the past 3 months
Number of subjects: 589
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk alcohol use
Number of subjects: 589
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 589
Study 26809204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related dysfunction
Number of subjects: 589
Study 26810133 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC3 allele A at rs4148412
Number of subjects: 316
Study 26810133 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC3 allele G at rs729923
Number of subjects: 316
Study 26810139 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Telephonic Assessment (ATA) calls
Number of subjects: 125
Study 26810441 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for allergic rhinitis
Number of subjects: 260
Study 26810441 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of extranasal symptoms
Number of subjects: 260
Study 26810581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly Pemetrexed (PEM) at 500 mg/m(2) combined with weekly Cisplatin (CDDP) and standard dose External Beam Radiation Therapy (EBRT)
Number of subjects: 10
Study 26810651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 39
Study 26810651 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 39
Study 26810651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 39
Study 26810651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 39
Study 26810651 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (two formulations)
Number of subjects: 39
Study 26810651 — intervention group
Group type: COMPARATOR
Intervention: HIV status
Number of subjects: 39
Study 26810758 — intervention group
Group type: EXPERIMENTAL
Intervention: End tidal CO2 (etco2) measurement greater than or equal to 50 mm Hg
Number of subjects: 201
Study 26810758 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score at inclusion
Number of subjects: 201
Study 26811129 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet lower in sodium and protein and higher in fruits, vegetables, and water for 4 weeks
Number of subjects: 12
Study 26811163 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported rehospitalizations
Number of subjects: 10643
Study 26811163 — intervention group
Group type: COMPARATOR
Intervention: Medical bills
Number of subjects: 10643
Study 26812041 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPP (Mood Action Psychology Programme)
Number of subjects: 14
Study 26812041 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly mood monitoring and treatment target data
Number of subjects: 14
Study 26812512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (EPA+DHA: 2.4 g/d)
Number of subjects: 21
Study 26812512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 21
Study 26812968 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR (waist-to-height ratio)
Number of subjects: 730
Study 26812968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass, heart rate, stature
Number of subjects: 730
Study 26812968 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 730
Study 26813675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment (≥5 cycles)
Number of subjects: 0
Study 26813675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib treatment (≥1 year)
Number of subjects: 0
Study 26813675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib exposure
Number of subjects: 0
Study 26813737 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodHacker intervention (n=150)
Number of subjects: 300
Study 26813737 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodHacker intervention (n=150) with EAP access
Number of subjects: 300
Study 26813737 — intervention group
Group type: COMPARATOR
Intervention: Alternative care (n=150)
Number of subjects: 300
Study 26814219 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient pulmonary rehabilitation (PR) program for 8 weeks
Number of subjects: 11
Study 26814234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical venous filling (CVF) assessed with dynamic CT angiography
Number of subjects: 88
Study 26814234 — intervention group
Group type: COMPARATOR
Intervention: Model without CVF information
Number of subjects: 88
Study 26814884 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon therapy for stress urinary incontinence
Number of subjects: 0
Study 26814884 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-derived stem cells for stress urinary incontinence
Number of subjects: 0
Study 26814884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation for overactive bladder
Number of subjects: 0
Study 26814884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical liposomes for drug delivery in interstitial cystitis/painful bladder syndrome
Number of subjects: 0
Study 26817140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose breath-print analysis
Number of subjects: 52
Study 26817280 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary HOM and body mass index
Number of subjects: 54
Study 26817280 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA dosage regimen based on urinary HOM
Number of subjects: 54
Study 26817606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity aerobic exercise training, performed four times per week for 12 weeks.
Number of subjects: 22
Study 26818566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based antiretroviral therapy with artemether-lumefantrine treatment
Number of subjects: 34
Study 26818566 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral-naïve group with artemether-lumefantrine treatment
Number of subjects: 34
Study 26818566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir group
Number of subjects: 34
Study 26818566 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral-naïve group
Number of subjects: 34
Study 26818847 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot walking sessions for 45 min daily over 20 sessions
Number of subjects: 3
Study 26819054 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+)CD38(-) leukemia cells with high aldehyde dehydrogenase activity
Number of subjects: 109
Study 26819054 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34(+)CD38(-) leukemia cells with intermediate aldehyde dehydrogenase expression
Number of subjects: 109
Study 26819054 — intervention group
Group type: EXPERIMENTAL
Intervention: No CD34(+) leukemia cells
Number of subjects: 109
Study 26819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cell (MSC) infusion, 2 infusions 1 week apart after 8 weeks of MSC culture expansion.
Number of subjects: 10
Study 26819296 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous MSC treatment
Number of subjects: 10
Study 26819573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce heavy drinking among Hispanics
Number of subjects: 0
Study 26819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium (2×256 mg, equivalent to 400 mg standard ibuprofen)
Number of subjects: 226
Study 26819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ibuprofen (2×200 mg)
Number of subjects: 226
Study 26819724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 26819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium
Number of subjects: 226
Study 26819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ibuprofen
Number of subjects: 226
Study 26819724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium vs Standard ibuprofen
Number of subjects: 226
Study 26819748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (TNFi + csDMARD such as methotrexate)
Number of subjects: 519
Study 26819748 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (TNFi only)
Number of subjects: 519
Study 26819752 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + MTX (arm AM)
Number of subjects: 31
Study 26819752 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (arm M)
Number of subjects: 31
Study 26820403 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional high-resolution anorectal manometry (3DHRAM)
Number of subjects: 61
Study 26820771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermenstrual bleeding
Number of subjects: 549
Study 26820771 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal bleeding
Number of subjects: 549
Study 26821198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 common depression rating scales (1 self-report, 3 clinician-report)
Number of subjects: 3509
Study 26821198 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall depression levels
Number of subjects: 3509
Study 26821198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum-scores of depression
Number of subjects: 3509
Study 26821583 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr-EES
Number of subjects: 2010
Study 26822149 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cancer therapy (iCat) recommendations based on tumor profiling
Number of subjects: 100
Study 26822149 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy based on iCat recommendations
Number of subjects: 100
Study 26822149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor profiling for actionable alterations
Number of subjects: 100
Study 26822149 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of alterations with clinical significance
Number of subjects: 100
Study 26822149 — intervention group
Group type: EXPERIMENTAL
Intervention: Common actionable alterations leading to iCat recommendations
Number of subjects: 100
Study 26822279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg low-dose aspirin
Number of subjects: 29
Study 26822279 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin challenges (up to 325 mg)
Number of subjects: 29
Study 26822328 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic personalized feedback via reinforcement learning
Number of subjects: 0
Study 26822328 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26822963 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock and cardiogenic shock patients (n=90)
Number of subjects: 90
Study 26822963 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors (n=5)
Number of subjects: 90
Study 26822963 — intervention group
Group type: COMPARATOR
Intervention: Septic patients (n=10)
Number of subjects: 90
Study 26822963 — intervention group
Group type: COMPARATOR
Intervention: Acute myocardial infarction or patients with prolonged acute arrhythmia (n=10)
Number of subjects: 90
Study 26823177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemrix (adjuvanted A/H1N1 2009 pandemic influenza vaccine)
Number of subjects: 91
Study 26823478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (ISIS-SMNRx or ISIS 396443) administered intrathecally during lumbar punctures.
Number of subjects: 28
Study 26823498 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (cardiac resynchronization therapy with defibrillator)
Number of subjects: 537
Study 26823498 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator only therapy
Number of subjects: 537
Study 26823498 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 537
Study 26823561 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training (n = 3 expert interpreters)
Number of subjects: 82
Study 26823561 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic training (n = 5 naïve interpreters)
Number of subjects: 82
Study 26823561 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment
Number of subjects: 82
Study 26823971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac-OD (once-daily tacrolimus)
Number of subjects: 60
Study 26823971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 *1/*3 (expressers)
Number of subjects: 60
Study 26823971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined expresser groups (*1/*1 & *1/*3)
Number of subjects: 60
Study 26824275 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 120
Study 26824275 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to Regional Tumor Registry (RTR)
Number of subjects: 120
Study 26824901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical injection of 100 U onabotulinumtoxinA (Botox)
Number of subjects: 80
Study 26824940 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. acyclovir, 5 mg/kg infused over 60 min (using ideal body weight for obese patients)
Number of subjects: 14
Study 26824940 — intervention group
Group type: COMPARATOR
Intervention: i.v. acyclovir, 5 mg/kg infused over 60 min (using total body weight for normal-weight patients)
Number of subjects: 14
Study 26825111 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of Internet-based CBT with limited telephone and e-mail support
Number of subjects: 0
Study 26825111 — intervention group
Group type: COMPARATOR
Intervention: Static webpage listing anxiety resources (Control)
Number of subjects: 0
Study 26825111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-consequence analysis
Number of subjects: 0
Study 26825111 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection at baseline, treatment completion, and at a 3-month follow-up
Number of subjects: 0
Study 26825137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention (varied by cognitive processing level and choice of argument topics)
Number of subjects: 350
Study 26825137 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal self-persuasion intervention identified in Stage 2
Number of subjects: 350
Study 26825137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-persuasion intervention
Number of subjects: 350
Study 26825170 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF816
Number of subjects: 0
Study 26825170 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF816 + INC280 (cMET inhibitor)
Number of subjects: 0
Study 26825231 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 3389
Study 26825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate Clearance (LC)
Number of subjects: 31
Study 26825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory Flow Index (MFI)
Number of subjects: 31
Study 26825368 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in microcirculatory blood flow
Number of subjects: 31
Study 26825712 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 25 mg/kg per day
Number of subjects: 102
Study 26825712 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 102
Study 26825925 — intervention group
Group type: EXPERIMENTAL
Intervention: nuMoM2b-HHS study visit including psychosocial and medical history questionnaires, clinical measurements, and biological specimens obtained.
Number of subjects: 10038
Study 26825925 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective assessments of sleep-disordered breathing during pregnancy in a subcohort.
Number of subjects: 10038
Study 26826134 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC GOLD
Number of subjects: 51
Study 26826134 — intervention group
Group type: COMPARATOR
Intervention: ERACE
Number of subjects: 51
Study 26826513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amygdala
Number of subjects: 0
Study 26826513 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Superior Temporal Sulcus (STS)
Number of subjects: 0
Study 26826513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusiform Face Area (FFA)
Number of subjects: 0
Study 26826513 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Inferior Temporal Cortex (aIT)
Number of subjects: 0
Study 26826513 — intervention group
Group type: COMPARATOR
Intervention: Amygdala and STS
Number of subjects: 0
Study 26826513 — intervention group
Group type: COMPARATOR
Intervention: FFA and aIT
Number of subjects: 0
Study 26826517 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo 3 T myelin-sensitive images (T1w over T2w ratio images)
Number of subjects: 0
Study 26826517 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo 7 T myelin-sensitive images (T1w over T2*w ratio images)
Number of subjects: 0
Study 26826517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo proton density-weighted images
Number of subjects: 0
Study 26826517 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed segmentation scheme
Number of subjects: 0
Study 26827109 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 156
Study 26827109 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) targeting thalamus, globus pallidus internus, internal capsule, and nucleus accumbens
Number of subjects: 156
Study 26827109 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 156
Study 26827659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-doxorubicin-dexamethasone reinduction
Number of subjects: 110
Study 26827881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 76
Study 26827881 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 76
Study 26828531 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I (cTnI) levels in patients with UMI
Number of subjects: 235
Study 26828531 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in patients with UMI
Number of subjects: 235
Study 26828531 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 levels in patients with UMI
Number of subjects: 235
Study 26829246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during TKA
Number of subjects: 0
Study 26829246 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26829377 — intervention group
Group type: EXPERIMENTAL
Intervention: GADD34 gene expression in peripheral blood mononuclear cells (PBMC) of RA patients
Number of subjects: 75
Study 26829377 — intervention group
Group type: EXPERIMENTAL
Intervention: GADD34 gene expression in PBMC of RA patients
Number of subjects: 75
Study 26829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG secretion
Number of subjects: 27
Study 26829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG oxidation
Number of subjects: 27
Study 26829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL-TG concentration
Number of subjects: 27
Study 26829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suppression of VLDL particle size
Number of subjects: 27
Study 26829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suppression of endogenous glucose production
Number of subjects: 27
Study 26829444 — intervention group
Group type: COMPARATOR
Intervention: T2D
Number of subjects: 371
Study 26829444 — intervention group
Group type: COMPARATOR
Intervention: T1D
Number of subjects: 371
Study 26829444 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D and T1D combined
Number of subjects: 371
Study 26829928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intakes, physical activity levels, and anthropometric measurements
Number of subjects: 9000
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/H1N1 infection (cases)
Number of subjects: 415
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics adapted to sputum colonization (cases)
Number of subjects: 415
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment (cases)
Number of subjects: 415
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatments (cases)
Number of subjects: 415
Study 26830335 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatments (controls)
Number of subjects: 415
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (FEV1)
Number of subjects: 415
Study 26830335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum colonization
Number of subjects: 415
Study 26830930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for PTSD
Number of subjects: 19
Study 26830930 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review of effective PTSD treatments
Number of subjects: 19
Study 26830930 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from patients and providers on PtDA
Number of subjects: 19
Study 26830967 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital TTP patients with renal insufficiency (n=13)
Number of subjects: 32
Study 26831232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)
Number of subjects: 100
Study 26831486 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions to promote colorectal cancer screening
Number of subjects: 102
Study 26831486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of procedure and concern about taking a powerful laxative
Number of subjects: 102